Clinical Trials Logo

Gastric Cancer clinical trials

View clinical trials related to Gastric Cancer.

Filter by:

NCT ID: NCT03272984 Completed - Gastric Cancer Clinical Trials

ERAS for Patients Received Neoadjuvant Chemotherapy

ERASNAC
Start date: April 1, 2015
Phase: N/A
Study type: Interventional

Patients received neoadjuvant chemotherapy with locally advanced gastric caner undergo the enhanced recovery after surgery (ERAS) programs or the standard cares (SC) programs.

NCT ID: NCT03271073 Recruiting - Gastric Cancer Clinical Trials

A Study of Apatinib Combined With S1 in Patients With Advanced Gastric Cancer

Start date: February 1, 2016
Phase: Phase 2
Study type: Interventional

Antiangiogenesis therapy plays an important role in cancer treatment. Apatinib showed good safety and efficacy as third-line therapy for advanced gastric cancer.We conducted this trial to investigate the safety and efficacy of apatinib combined with S1 after failure of first-line chemotherapy in advanced gastric cancer or gastroesophageal junction carcinoma patients.

NCT ID: NCT03264807 Recruiting - Gastric Cancer Clinical Trials

Lymph Node 14v Dissection in Clinical Stage T3N+, T4N+ of Gastric Cancer

Start date: August 6, 2015
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the survival rate according to the presence or absence of 14v lymph node dissection.

NCT ID: NCT03263741 Recruiting - Gastric Cancer Clinical Trials

Exploratory Study on the Paclitaxel + S-1 + Oxaliplatin (PSOX) for Locally Advanced or Advanced Gastric Cancer

Start date: April 1, 2017
Phase: Phase 2
Study type: Interventional

Explore the Efficiency and Safety of Paclitaxel + S-1 + Oxaliplatin (PSOX) Chemotherapy in the Patients with Locally Advanced or Advanced Gastric Cancer

NCT ID: NCT03259867 Recruiting - Clinical trials for Hepatocellular Carcinoma

Combination of TATE and PD-1 Inhibitor in Liver Cancer

TATE-PD1
Start date: July 1, 2017
Phase: Phase 2
Study type: Interventional

This is a multi-center, open-label phase IIA study that investigates the preliminary efficacy of Trans-arterial Tirapazamine Embolization (TATE) treatment of liver cancer followed by a PD-1 checkpoint inhibitor (nivolumab). Patients with two types of cancers will be enrolled, advanced hepatocellular carcinoma (HCC),and metastatic gastric cancer. All enrolled patients need to have liver lesions and have progressed on a prior immune checkpoint inhibitor.

NCT ID: NCT03258034 Enrolling by invitation - Gastric Cancer Clinical Trials

A Feasibility Study for Convernsion Therapy Using S1/Paclitaxel Chemotherapy Plus Apatinib in ELM Gastric Cancer

Start date: August 24, 2017
Phase: Phase 2
Study type: Interventional

The prognosis of Extensive lymph nodes metastatic(ELM) gastric cancer is poor. Chemotherapy occasionally converts it to a resectable cancer. Previous studies showed patients with ELM gastric cancer may obtain a survival benefit from chemotherapy and subsequent curative surgery. The key of conversion therapy of ELMGC is the high response rate. Apatinib, a novel targeted inhibitor of VEGF receptor 2 (VEGFR2), shows significant antitumor activity in the patients with GC. On the basis of our previous Ahead-G325 study, The purpose of this study is to investigate the efficacy and safety of S1/Paclitaxel chemotherapy plus Apatinib in the conversion therapys of ELM gastric cancer.

NCT ID: NCT03257280 Recruiting - Gastric Cancer Clinical Trials

Trial on Impact on the Hospital Stay, of an Early Oral Nutrition Protocol Applied to Patients After Total Gastrectomy. (DOPGT_2015)

Start date: October 20, 2017
Phase: N/A
Study type: Interventional

This is a prospective randomized controlled clinical trial to clarify the effect of early oral nutrition introduction after total gastrectomy in gastric cancer patients on the length of hospital stay, comparing an experimental group vs control group.

NCT ID: NCT03253939 Completed - Gastric Cancer Clinical Trials

Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Peritoneal Carcinomatosis From Gastric Cancer

CYTO-CHIP
Start date: February 1, 2017
Phase: N/A
Study type: Observational

Gastric cancer associated peritoneal carcinomatosis has a poor prognosis with a median survival of less than one year. Systemic chemotherapy including targeted agents has not been found to significantly increase the survival in Gastric cancer associated peritoneal carcinomatosis. Since recurrent gastric cancer remains confined to the abdominal cavity in many patients, regional therapies like aggressive cytoreductive surgery and hyperthermic intraperitoneal chemotherapy have been investigated for Gastric cancer associated peritoneal carcinomatosis. Hyperthermic intraperitoneal chemotherapy has been used for three indications in Gastric Cancer- as an adjuvant therapy after a curative surgery, hyperthermic intraperitoneal chemotherapy has been shown to improve survival and reduce peritoneal recurrences in many randomised trials in Asian countries; as a definitive treatment in established PC, hyperthermic intraperitoneal chemotherapy along with cytoreductive surgery is the only therapeutic modality that has resulted in long-term survival in select groups of patients. While the results of randomised trials of adjuvant hyperthermic intraperitoneal chemotherapy from western centres are awaited, the role of hyperthermic intraperitoneal chemotherapy in the treatment of Gastric cancer associated peritoneal carcinomatosis is still evolving and needs larger studies before it is accepted as a standard of care.

NCT ID: NCT03253185 Terminated - Gastric Cancer Clinical Trials

A Study of SC-007 in Subjects With Advanced Cancer

Start date: September 13, 2017
Phase: Phase 1
Study type: Interventional

This is a multicenter, open-label, Phase 1 study in participants with colorectal cancer (CRC) or gastric cancer to study the safety and tolerability of SC-007 and consists of Part A (dose regimen finding) in participants with CRC followed by Part A in participants with gastric cancer. Part B (dose expansion) will enroll participants into separate disease specific cohorts of CRC or gastric cancer.

NCT ID: NCT03253107 Recruiting - Gastric Cancer Clinical Trials

Predicting Biomarker of Gastric Cancer Chemotherapy Response

Start date: November 30, 2015
Phase:
Study type: Observational

- discovery and validation of biomarker predicting gastric cancer chemotherapy response - Analysis for expression level of mRNA using Next generation sequencing in gastric cancer tissue by chemotherapy response - Analysis for expression level of miRNA using Next generation sequencing in gastric cancer tissue and blood by chemotherapy response - Validation of mRNA and miRNA using qRT-PCR in multiple independent cohort - Biological biomarkers-clinical factor combined prediction model of gastric cancer chemotherapy response